Alerts and notices · new
Know as soon as an alert is published on a drug you follow.
Every day we check the EMA safety communications, referrals and shortages and the FDA recalls and shortages, and link them to the drugs.
- Alerts checked every day
Safety communications to healthcare professionals, safety referrals and EMA shortages; FDA recalls and shortages. Always with the link to the official document.
- Follow any drug
Drugs in development and more than 5,000 medicines authorised in the EU and the US, even if they have no alerts today.
- An email the same day
You get an email for every new alert on the drugs you follow and, every Monday, a summary of development news. Included in early access.
How it works
From scattered registries to a verified pipeline.
Collect
We download structured data from official registries and refresh it regularly; the extraction date is always shown.
Verify
Development codes, generic and brand names are linked only under published rules, checked by hand on samples.
Monitor
Every week we detect changes and development events: new trials, phase and date changes, stopped trials, EMA and FDA opinions and approvals. Follow drugs, companies and diseases: you get an email on every new alert on followed drugs and a summary every Monday.
Who it's for
For those who follow drugs before and after approval.
Physicians and researchers
Recruiting trials, drugs coming for the diseases they follow, alerts on the medicines they prescribe.
Pharma and biotech companies
Competitors’ pipelines by therapeutic area, phases, events and dates, without the cost of traditional databases.
Consultants and analysts
Verified, exportable lists with the source of every fact, ready for clients and reports.
Investors
Regulatory calendar, patent and exclusivity expiries, listed companies linked to SEC filings.
Pharmacists and patient associations
Safety alerts and shortages from the agencies of six countries, with the official document, the same day.
Features
What you find in Phuturdex.
Multi-variable search
Phase, disease (also in Italian, French and German), company, country, trial status, approvals, designations and events.
One page per drug
Verified identity, US and EU approvals, designations, patents and exclusivities, development events and all trials, with source and date.
Diseases and companies
For every disease and sponsor, the pipeline by phase with competitors and upcoming dates; listed companies linked to SEC filings.
Regulatory calendar
Expected EU decisions, expected end of phase III trials, patent and exclusivity expiries, estimated launch windows.
Monitoring and alerts
Follow drugs, companies and diseases and see what changed; an email at every new alert on the drugs you follow and the Monday summary.
Export and reports
Excel and CSV with source and reliability columns, PDF reports and sheets; API in development.
Alerts on marketed drugs
Add-on service: EMA safety communications, referrals and shortages, FDA recalls and shortages, linked to the drugs. Checked every day.
Public method
Linking rules and quality checks are published; every data point leads to the official source, which remains the only reference.
Data sources
Public, official sources. The value is in how we verify and connect them.
Every data point links to the original source and shows the extraction date. The rules we use to connect names and trials are published, together with the results of our quality checks.
Live. Clinical trials registry of the U.S. National Library of Medicine, covering trials worldwide.
clinicaltrials.govComing soon. The European Union's official clinical trials registry, run by the EMA.
euclinicaltrials.euLive. Approved drugs (Drugs@FDA), official registry of substances and development codes (GSRS), biologics and cell and gene therapies (Purple Book), patents and exclusivities (Orange Book), orphan drugs.
open.fda.govLive. Authorised medicines and opinions, medicines under evaluation, PRIME scheme, orphan designations and safety alerts of the European Medicines Agency.
ema.europa.euEarly access
Everything included, free, until 31 March 2027.
No plan to choose, no card, no automatic renewal: you enter with your email and use the whole service. In return we only ask you to tell us what works and what is missing.
What you get right away
The same complete service for everyone, from the first sign-in.
- Full search, every result: by disease (also in Italian, French and German), phase, country, company and trial status
- Disease and company pages, regulatory calendar, PDF sheet of every drug
- Follow drugs and medicines: an email at every new EMA, FDA, AIFA, ANSM, AEMPS, BfArM and MHRA alert, and the Monday summary
- Excel export and PDF reports, with a daily limit that protects the data
Founders
Early access is how we build Phuturdex together with the people who use it. Who signs up in this phase is a founder.
- When paid plans start we will write to you at least 30 days in advance
- Reserved founder terms on the plans
- No automatic charge: at the end of the phase you decide whether to continue
What we ask in return
No payment details: we just need to know what works and what is missing.
- The “Suggestions” button in Phuturdex: we read everything
- After the first week, an email with three questions: one tap to answer
- If it is useful to you, invite a colleague from Phuturdex
Physicians and researchers
For those who treat patients, take part in trials or do research: what you find and how to use it in daily work.
- The same full access, free until 31 March 2027
- Safety alerts and shortages on the medicines you prescribe
- Disease pages with recruiting trials and Orphanet prevalence